Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy
about
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humansThe Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon TherapyContribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American PatientsHCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma.Novel nucleotide and amino acid covariation between the 5'UTR and the NS2/NS3 proteins of hepatitis C virus: bioinformatic and functional analyses.Evidence for separation of HCV subtype 1a into two distinct clades.Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1α and PKR.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapyWithin-host nucleotide diversity of virus populations: insights from next-generation sequencing.Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms.Use of illumina deep sequencing technology to differentiate hepatitis C virus variants.Heterogeneity and new epitopes of hepatitis C virus genotype 4.Resistance mechanisms in HCV: from evolution to intervention.HCV genetic variability: from quasispecies evolution to genotype classification.Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liverEpistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.Genome-wide networks of amino acid covariances are common among viruses.Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay.Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C.In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections.Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B.
P2860
Q27487540-B38D6AB1-0DE4-4945-B247-6DD57EEEFC54Q27489040-875AFF27-380E-45DB-BC23-D3C8FF3A56FCQ27490885-CE396EEB-467F-4821-87D5-95E8F12F1AB1Q33982230-A921B38C-BDA5-4C3B-87C3-7EF31BFEE957Q34043316-3CE3CCE1-7468-45B2-93A7-7F7054F86270Q34242504-E367E179-1BD0-40B4-A323-98D00848F1D4Q34475801-614080AE-7D03-4BD4-A52F-00FF55F73003Q34489239-2095EB04-068C-4038-BBC0-37E2FB36E7E3Q34577134-3CAD1823-4611-4AD8-8804-4CA6862B274DQ35047735-95F65277-9355-4555-9A31-B73C64E8BEB1Q35230421-B994458F-0E00-49D1-820B-4CBC3991EA7FQ35806939-1C3D2DA1-33C1-41CC-938B-31E354EE62D5Q37228726-E98513A7-E7EE-4E9F-9D8A-47A51CBF47D1Q37228736-96C5A1DE-C6AD-4DA9-8801-06D66C325AE0Q37425275-4A1B3AD4-DDCA-4FFF-A73D-D7595E5D2D7FQ37684887-D53E5CCF-CAAD-452D-B62A-6DCBF9EF3E43Q38074272-03581389-A6DD-490A-BC26-C05E5A05D6C1Q40481366-A6D53520-44CD-42BD-92E2-132FEC52CC1BQ41841986-73ED544D-28A9-4D32-84B6-06A5DC4BE02EQ42064403-1BA8F2D4-36FD-423A-A41D-81C835A3F25BQ42270437-37DED4BD-E8C6-49E1-87F1-D275BD852E3DQ42731526-B19ACC78-CE58-4AEE-BC35-856BC38AADD6Q42861856-794D6F51-D240-41F1-9BD5-36A39C9DA553Q42978470-E4D38450-D36B-479A-BB81-2C32E41B030CQ45325483-D010685D-CBBF-4762-BBB4-2453D4465C99Q54088746-8B79C659-20F6-4EF8-8779-7A39E24D883E
P2860
Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@ast
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@en
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@nl
type
label
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@ast
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@en
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@nl
prefLabel
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@ast
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@en
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@nl
P2093
P2860
P1433
P1476
Hepatitis C Virus Diversity an ...... Frame during Antiviral Therapy
@en
P2093
John E Tavis
Nathan A Cannon
Xiaofeng Fan
P2860
P356
10.1371/JOURNAL.PONE.0002123
P407
P577
2008-05-07T00:00:00Z